Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy

Biomaterials

Volumn 34, Issue 13, 2013, Pages 3447-3458

  Zhang, Yuan ^a   Kim, William Y ^b   Huang, Leaf ^a  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Apoptosis; Cell cycle progression; Gemcitabine triphosphate; LCP nanoparticle; Proliferation

Indexed keywords

ANTI-CANCER AGENTS; CELL CYCLE; CELL-CYCLE PROGRESSION; DNA SYNTHESISS; GEMCITABINE; IN-VIVO; INHIBITION OF TUMOR GROWTH; NON SMALL CELL LUNG CANCER; NUCLEOSIDE ANALOGS; PANCREATIC CANCERS; PRODRUGS; PROLIFERATION; PROOF OF PRINCIPLES; S-PHASE; SYSTEMIC ADMINISTRATION; SYSTEMIC DELIVERIES; THERAPEUTIC APPLICATION; THERAPEUTIC EFFICACY; TRIPHOSPHATE; TUMOR CELLS;

CELL DEATH; CELL PROLIFERATION; DISEASES; NANOPARTICLES; NUCLEOTIDES; PHOSPHORYLATION; TUMORS;

DRUG PRODUCTS;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; AMIDE; CALCIUM PHOSPHATE; CASPASE 3; CASPASE 7; GEMCITABINE; GEMCITABINE TRIPHOSPHATE; LIPID CALCIUM PHOSPHATE NANOPARTICLE; MACROGOL; NANOPARTICLE; PHOSPHATIDYLETHANOLAMINE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MOUSE; NANOENCAPSULATION; NEPHROTOXICITY; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCIUM; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTIDINE TRIPHOSPHATE; ENZYME ACTIVATION; FEMALE; HUMANS; LIPIDS; LUNG NEOPLASMS; MICE; MICE, NUDE; NANOPARTICLES; PANCREATIC NEOPLASMS; PARTICLE SIZE; PHOSPHATES; POLY(ADP-RIBOSE) POLYMERASES; POLYETHYLENE GLYCOLS; S PHASE; STATIC ELECTRICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874256639     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.01.063     Document Type: Article

References (33)

1. Achanta G., Pelicano H., Feng L., Plunkett W., Huang P. Interaction of p53 and DNA- PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res 2001, 61(24):8723-8729.
2. Parker W.B. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev 2009, 109(7):2880-2893.
3. Senanayake T.H., Warren G., Vinogradov S.V. Novel anticancer polymeric conjugates of activated nucleoside analogues. Bioconjug Chem 2011, 22(10):1983-1993.
4. van Moorsel C.J., Peters G.J., Pinedo H.M. Gemcitabine: future prospects of single-agent and combination studies. Oncologist 1997, 2(3):127-134.
5. Hung S.W., Mody H.R., Govindarajan R. Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett 2012, 320(2):138-149.
6. Allain V., Bourgaux C., Couvreur P. Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices. Nucleic Acids Res 2012, 40(5):1891-1903.
7. Rejiba S., Reddy L.H., Bigand C., Parmentier C., Couvreur P., Hajri A. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine 2011, 7(6):841-849.
8. Li J., Chen Y.C., Tseng Y.C., Mozumdar S., Huang L. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release 2010, 142(3):416-421.
9. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46(12 Pt 1):6387-6392.
10. Li S.D., Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta 2009, 1788(10):2259-2266.
11. Banerjee R., Tyagi P., Li S., Huang L. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer 2004, 112(4):693-700.
12. Li J., Yang Y., Huang L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release 2012, 158(1):108-114.
13. Zhang Y., Wang X., Wang J., Zhang X., Zhang Q. Octreotide-modified polymeric micelles as potential carriers for targeted docetaxel delivery to somatostatin receptor overexpressing tumor cells. Pharm Res 2011, 28(5):1167-1178.
14. Risbood P.A., Kane C.T., Hossain M.T., Vadapalli S., Chadda S.K. Synthesis of gemcitabine triphosphate (dFdCTP) as a tris(triethylammonium) salt. Bioorg Med Chem Lett 2008, 18(9):2957-2958.
15. Karl D.M., Craven D.B. Effects of alkaline phosphatase activity on nucleotide measurements in aquatic microbial communities. Appl Environ Microbiol 1980, 40(3):549-561.
16. Kim I.Y., Kang Y.S., Lee D.S., Park H.J., Choi E.K., Oh Y.K., et al. Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J Control Release 2009, 140(1):55-60.
17. Johnson S.A. Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies. Clin Pharmacokinet 2000, 39(1):5-26.
18. Cohen G.M. Caspases: the executioners of apoptosis. Biochem J 1997, 326(Pt 1):1-16.
19. Arya G., Vandana M., Acharya S., Sahoo S.K. Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy. Nanomedicine 2011, 7(6):859-870.
20. Tang S.N., Fu J., Shankar S., Srivastava R.K. EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer. PLoS One 2012, 7(2):e31067.
21. Andreeva E.R., Orekhov A.N. Evaluation of cell proliferation in human atherosclerotic lesions. Methods Mol Med 2001, 52:213-218.
22. Hornick J.R., Spitzer D., Goedegebuure P., Mach R.H., Hawkins W.G. Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands. Surgery 2012, 152(3 Suppl. 1):S152-S156.
23. Riganas S., Papanastasiou I., Foscolos G.B., Tsotinis A., Bourguignon J.J., Serin G., et al. Synthesis, sigma(1), sigma(2)-receptors binding affinity and antiproliferative action of new C1-substituted adamantanes. Bioorg Med Chem 2012, 20(10):3323-3331.
24. Everaert H., Flamen P., Franken P.R., Verhaeghe W., Bossuyt A. Sigma-receptor imaging by means of I123-IDAB scintigraphy: clinical application in melanoma and non-small cell lung cancer. Anticancer Res 1997, 17(3B):1577-1582.
25. White J.C., Rathmell J.P., Capizzi R.L. Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells. J Clin Invest 1987, 79(2):380-387.
26. Brusa P., Immordino M.L., Rocco F., Cattel L. Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. Anticancer Res 2007, 27(1A):195-199.
27. Immordino M.L., Brusa P., Rocco F., Arpicco S., Ceruti M., Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release 2004, 100(3):331-346.
28. Lansakara P.D., Rodriguez B.L., Cui Z. Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles. Int J Pharm 2012, 429(1-2):123-134.
29. Sarpietro M.G., Ottimo S., Giuffrida M.C., Rocco F., Ceruti M., Castelli F. Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers. Int J Pharm 2011, 406(1-2):69-77.
30. Li Q., Du Y.Z., Yuan H., Zhang X.G., Miao J., Cui F.D., et al. Synthesis of lamivudine stearate and antiviral activity of stearic acid-g-chitosan oligosaccharide polymeric micelles delivery system. Eur J Pharm Sci 2010, 41(3-4):498-507.
31. Meier C., Balzarini J. Application of the cycloSal-prodrug approach for improving the biological potential of phosphorylated biomolecules. Antiviral Res 2006, 71(2-3):282-292.
32. Zhang Y., Satterlee A., Huang L. In vivo gene delivery by nonviral vectors: overcoming hurdles?. Mol Ther 2012, 20(7):1298-1304.
33. Xu Y., Szoka F.C. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 1996, 35(18):5616-5623.